[1] Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality[J]. Eur Urol, 2015,67:519-530.[2] Young A C, Craven R A, Cohen D, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma[J]. Clin Cancer Res, 2009,15(24):7582-7592.[3] Ghosh M G, Thompson D A, Weigel R J. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer[J]. Cancer Res, 2000,60(22):6367-6375.[4] Dunbier A K, Anderson H, Ghazoui Z, et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women[J]. J Clin Oncol, 2010,28(7):1161-1167.[5] Kim H, Abd Elmageed Z Y, Ju J, et al. PDZK is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotesestrogen-mediated growth[J]. Mol Med, 2013,19:253-262.[6] Kocher O, Comella N, Gilchrist A, et al. PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT(MRP2), the multidrug resistance-associated protein[J]. Lab Invest, 1999,79(9):1161-1170.[7] Tsuchiya N, Sato K, Akao T, et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma[J]. Tohoku J Exp Med, 2001,195(2):101-113.[8] Ma N, Li L W, Cheng J L. Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients[J]. Oncol Lett, 2015,9(2):651-656.[9] Takahashi Y, Morales F C, Kreimann E L, et al. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling[J]. EMBO J, 2006,25(4):910-920.[10] Cheng S, Li Y, Yang Y, et al. Breast cancer-derived K172N, D301V mutations abolish Na+/H+ exchanger regulatory factor 1 inhibition of platelet-derived growth factor receptor signaling[J]. FEBS Lett, 2013,587(20):3289-3295. |